Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-21 6:38 pm Purchase | 2025-01-16 | 13D | Reneo Pharmaceuticals, Inc. RPHM | RiverVest Venture Fund III, L.P. | 196,198 1.550% | 196,198 (New Position) | Filing History |
| 2025-01-10 11:05 am Purchase | 2025-01-07 | 13D | Spruce Biosciences, Inc. SPRB | RiverVest Venture Fund III, L.P. | 23,460 4.200% | 23,460 (New Position) | Filing History |
| 2024-02-02 12:31 pm Unchanged | 2024-02-02 | 13D | Allakos Inc. ALLK | RiverVest Venture Fund III, L.P. | 0 0.000% | 0 (Unchanged) | Filing |
| 2023-05-30 4:52 pm Unchanged | 2023-05-30 | 13D | OnKure Therapeutics, Inc. OKUR | RiverVest Venture Fund III, L.P. | 0 0.000% | 0 (Unchanged) | Filing |
| 2023-05-30 4:48 pm Unchanged | 2023-05-30 | 13D | Spruce Biosciences, Inc. SPRB | RiverVest Venture Fund III, L.P. | 0 0.000% | 0 (Unchanged) | Filing |
| 2021-04-19 2:04 pm Unchanged | 2021-04-19 | 13D | OnKure Therapeutics, Inc. OKUR | RiverVest Venture Fund III, L.P. | 0 0.000% | 0 (Unchanged) | Filing |